THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback